Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Alcami has reached an agreement to be acquired by Madison Dearborn Partners (MDP).
read more
Made Scientific has been selected as manufacturer for NOVAKnee, a first-in-class living biologic total knee replacement being developed by researchers at Columbia University's School of Engineering and Vagelos College of Physicians and Surgeons under...
read more
Made Scientific recently held a ribbon-cutting ceremony to commemorate the grand opening of its new 60,000 sq. ft. GMP manufacturing facility and headquarters in Princeton, New Jersey.
read more
Thursday, August 28, 2025
Made Scientific announced the formation of its Scientific Advisory Board (SAB) with the appointments of Miguel Forte, M.D., Ph.D., Paul K. Wotton, Ph.D., Shishir Gadam, Ph.D., and Young K. Hong M.D.
read more
Made Scientific announced a significant expansion of its Princeton, New Jersey facility to meet increasing demand from late-phase and commercial clients and support the anticipated rise in approved advanced therapies.
read more
Thursday, October 02, 2025
Made Scientific, a cell therapy contract development and manufacturing organization (CDMO) and Syenex, a synthetic biology company specializing in targeted delivery technologies, announced a technology partnership to advance the scalability and ...
read more
Wednesday, April 22, 2026
Made Scientific and Regenicin announced a manufacturing relationship to advance NovaDerm, an autologous cultured skin substitute for severe burns and chronic wounds, toward a U.S. FDA Orphan product approval.
read more
Made Scientific and Pluristyx announced a strategic partnership to integrate Pluristyx Technology including GMP iPSC lines and derivative cell types, including induced natural killer (iNK) cells and induced mesenchymal stem cells (iMSCs), into Made ...
read more
Monday, September 08, 2025
Made Scientific and Hemogenyx Pharma announced a manufacturing partnership to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia (r/r...
read more
Tuesday, November 25, 2025
Under this collaboration, Cellergy Therapeutics will leverage Made Scientific's GMP manufacturing capabilities to implement and scale Cellergy's proprietary mitochondrial isolation and purification process. The work will support the production of ...
read more
Wednesday, April 24, 2019
Macrogen announced it has signed a supply contract with Exosome Plus to become the exclusive buyer of the exosome isolation kits developed by Exosome Plus.
read more
Macrogen has received GCLP (Good Clinical Laboratory Practice) accreditation from the Ministry of Food and Drug Safety (MFDS) in Korea.
read more
Macro Trials, a precision research clinical platform, launched today to transform clinical trials. The company’s founders incubated Macro Trials with INITIATE Studios, a venture studio that co-creates companies at the intersection of healthcare, life...
read more
Monday, February 05, 2024
mAbxience announced an agreement with Biosidus in which mAbxience will be responsible for the manufacture of the active ingredient Agalsidase Beta, developed by Biosidus as a biosimilar of Fabrazyme.
read more
Thursday, November 05, 2015
MabVax Therapeutics Holdings, a clinical-stage oncology drug development company, has completed manufacturing of the bulk clinical-quality drug substance of HuMab 5B1 in preparation for the planned initiation of two Phase I clinical trials with this ...
read more